Get the Stockscreener App
206.86
1.18%
-2.46
After Hours:
206.86
Overview
News
Price History
Option Chain
Financials
Discussions
Forecast
Stock Split
Dividend History
Quest Diagnostics Inc stock is traded at $206.86, with a volume of 1.67M.
It is down -1.18% in the last 24 hours and up +17.57% over the past month.
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the US. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk-assessment services, and information technology solutions.
See More
Previous Close:
$209.32
Open:
$211.8
24h Volume:
1.67M
Relative Volume:
1.54
Market Cap:
$22.80B
Revenue:
$10.52B
Net Income/Loss:
$999.00M
P/E Ratio:
24.74
EPS:
8.3628
Net Cash Flow:
$1.22B
1W Performance:
+7.57%
1M Performance:
+17.57%
6M Performance:
+15.77%
1Y Performance:
+25.87%
1-Day Range:
$206.81
$213.20
1-Week Range:
$187.58
$213.20
52-Week Range:
$157.20
$213.20
Quest Diagnostics Inc Stock (DGX) Company Profile
Name
Quest Diagnostics Inc
Sector
Industry
Phone
(973) 520-2700
Address
500 PLAZA DRIVE, SECAUCUS
Compare DGX vs TMO, DHR, IDXX, A, WAT
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
DGX
Quest Diagnostics Inc
|
206.86 | 23.08B | 10.52B | 999.00M | 1.22B | 8.3628 |
|
TMO
Thermo Fisher Scientific Inc
|
509.82 | 198.06B | 44.56B | 6.73B | 6.29B | 17.74 |
|
DHR
Danaher Corp
|
214.94 | 155.50B | 24.57B | 3.60B | 5.25B | 5.0475 |
|
IDXX
Idexx Laboratories Inc
|
617.20 | 51.80B | 4.30B | 1.06B | 1.04B | 13.08 |
|
A
Agilent Technologies Inc
|
124.88 | 36.46B | 6.95B | 1.30B | 1.15B | 4.5696 |
|
WAT
Waters Corp
|
319.83 | 32.29B | 3.17B | 642.63M | 539.81M | 10.77 |
Quest Diagnostics Inc Stock (DGX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-30-26 | Upgrade | Barclays | Equal Weight → Overweight |
| Aug-25-25 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Apr-02-25 | Initiated | Redburn Atlantic | Buy |
| Mar-04-25 | Downgrade | Citigroup | Buy → Neutral |
| Jan-06-25 | Upgrade | Leerink Partners | Market Perform → Outperform |
| Dec-17-24 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Dec-10-24 | Resumed | Jefferies | Buy |
| Oct-23-24 | Upgrade | Robert W. Baird | Neutral → Outperform |
| Aug-28-24 | Resumed | Evercore ISI | In-line |
| Jul-10-24 | Upgrade | Citigroup | Neutral → Buy |
| Feb-26-24 | Initiated | Leerink Partners | Market Perform |
| Feb-07-24 | Upgrade | Jefferies | Hold → Buy |
| Jan-03-24 | Initiated | Barclays | Equal Weight |
| Dec-12-23 | Upgrade | BofA Securities | Neutral → Buy |
| Jun-29-23 | Initiated | Piper Sandler | Neutral |
| May-02-23 | Downgrade | BofA Securities | Buy → Neutral |
| Apr-03-23 | Upgrade | Citigroup | Sell → Neutral |
| Jan-23-23 | Initiated | Evercore ISI | In-line |
| Nov-17-22 | Downgrade | Citigroup | Neutral → Sell |
| Aug-22-22 | Resumed | Morgan Stanley | Equal-Weight |
| Apr-04-22 | Downgrade | Citigroup | Buy → Neutral |
| Feb-23-22 | Downgrade | UBS | Buy → Neutral |
| Feb-02-22 | Downgrade | Jefferies | Buy → Hold |
| Jan-28-22 | Downgrade | Deutsche Bank | Buy → Hold |
| May-04-21 | Upgrade | UBS | Neutral → Buy |
| Mar-12-21 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Oct-21-20 | Upgrade | Argus | Hold → Buy |
| Jul-29-20 | Upgrade | KeyBanc Capital Markets | Sector Weight → Overweight |
| Jul-14-20 | Upgrade | BofA Securities | Neutral → Buy |
| Jun-09-20 | Upgrade | Wells Fargo | Underweight → Equal Weight |
| Jun-02-20 | Upgrade | Deutsche Bank | Hold → Buy |
| Apr-28-20 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Apr-27-20 | Upgrade | Citigroup | Neutral → Buy |
| Apr-27-20 | Upgrade | Wolfe Research | Underperform → Peer Perform |
| Mar-27-20 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Jan-08-20 | Initiated | Wells Fargo | Underweight |
| Jan-07-20 | Downgrade | Barclays | Overweight → Equal Weight |
| Dec-19-19 | Upgrade | BofA/Merrill | Underperform → Neutral |
| Jul-15-19 | Downgrade | Goldman | Neutral → Sell |
| Apr-02-19 | Upgrade | Jefferies | Hold → Buy |
| Mar-18-19 | Resumed | Credit Suisse | Neutral |
| Jan-31-19 | Downgrade | Argus | Buy → Hold |
| Jan-17-19 | Initiated | UBS | Neutral |
| Jan-03-19 | Downgrade | BofA/Merrill | Neutral → Underperform |
| Dec-03-18 | Downgrade | BofA/Merrill | Buy → Neutral |
| Nov-30-18 | Downgrade | Goldman | Buy → Neutral |
View All
Quest Diagnostics Inc Stock (DGX) Latest News
Quest Diagnostics (DGX): Analyst Raises Price Target to $235 | D - GuruFocus
Mizuho Securities Adjusts Quest Diagnostics PT to $235 From $210, Maintains Outperform Rating - marketscreener.com
Rothschild & Co Redburn Adjusts Quest Diagnostics PT to $224 From $200, Maintains Buy Rating - marketscreener.com
Forecasting The Future: 6 Analyst Projections For Quest Diagnostics - Benzinga
DGX Q4 Deep Dive: Consumer Testing and Advanced Diagnostics Fuel Growth Amid Margin Headwinds - Finviz
Quest Diagnostics (DGX): Truist Securities Raises Price Target A - GuruFocus
UBS Raises Price Target for Quest Diagnostics (DGX) to $210 | DG - GuruFocus
Deutsche Bank Adjusts Quest Diagnostics Price Target to $205 From $178, Maintains Hold Rating - marketscreener.com
DGX: Evercore ISI Group Raises Price Target for Quest Diagnostics | DGX Stock News - GuruFocus
Quest Diagnostics (DGX): Navigating the New Frontier of Advanced Diagnostics and AI Efficiency - FinancialContent
Quest Diagnostics Incorporated (DGX) Hit a 52 Week High, Can the Run Continue? - Yahoo Finance
Evercore ISI Adjusts Quest Diagnostics PT to $220 From $190, Maintains In Line Rating - marketscreener.com
Barclays Adjusts Quest Diagnostics PT to $225 From $210, Maintains Overweight Rating - marketscreener.com
Baird Adjusts Quest Diagnostics Price Target to $219 From $203, Maintains Neutral Rating - marketscreener.com
Quest Diagnostics Incorporated (NYSE:DGX) Q4 2025 Earnings Call Transcript - Insider Monkey
DGX: Jefferies Raises Target Price for Quest Diagnostics to $220 - GuruFocus
Truist Raises Price Target on Quest Diagnostics to $220 From $205, Keeps Hold Rating - marketscreener.com
Candriam S.C.A. Has $13.69 Million Stake in Quest Diagnostics Incorporated $DGX - MarketBeat
Quest Diagnostics Shares Jump on Q4 Beat; FY25 Revenue Rises, 2026 Outlook Raised - AlphaStreet News
Quest Diagnostics Inc. stock outperforms competitors on strong trading day - MSN
Quest Diagnostics Q4 Earnings Call Highlights - Yahoo Finance
Jefferies Maintains Buy on Quest Diagnostics (DGX) Feb 10, 2026 - Meyka
Quest Diagnostics: Q4 Earnings Snapshot - theheraldreview.com
Why Is Quest (DGX) Stock Soaring Today - Finviz
Quest Diagnostics (DGX) Earnings Call Transcript - The Globe and Mail
Quest Diagnostics Inc (DGX) Q4 2025 Earnings Call Highlights: St - GuruFocus
Why Is Quest Diagnostics Stock Soaring Tuesday?Quest Diagnostics (NYSE:DGX) - Benzinga
Quest's (NYSE:DGX) Q4 CY2025: Beats On Revenue - Finviz
Quest Diagnostics' Q4 Earnings & Revenues Beat Estimates, Stock Up - sharewise.com
Quest Diagnostics (DGX) Sees Significant Stock Price Surge - GuruFocus
Quest Diagnostics Incorporated announces an Increase in Equity Buyback - marketscreener.com
Quest Diagnostics Stock Gains 7% Over Increased Profit In Q4 - Nasdaq
Tranche Update on Quest Diagnostics Incorporated's Equity Buyback Plan announced on October 20, 2010. - marketscreener.com
Quest Diagnostics hits 52-week high on outlook (DGX:NYSE) - Seeking Alpha
Quest Diagnostics (NYSE:DGX) Sets New 12-Month High Following Strong Earnings - MarketBeat
Quest Diagnostics stock hits all-time high at $198.00 By Investing.com - Investing.com Canada
Quest Diagnostics stock hits all-time high at $198.00 - Investing.com
Quest Diagnostics Seeks Independent Lab Acquisitions - marketscreener.com
Quest Diagnostics forecasts 2026 profit, revenue above estimates on lab test demand - marketscreener.com
Quest Diagnostics (NYSE:DGX) Issues Earnings Results, Beats Estimates By $0.07 EPS - MarketBeat
Quest Diagnostics Incorporated Provides Earnings Guidance for the Full Year 2026 - marketscreener.com
Quest Diagnostics (DGX) Beats Q4 Earnings and Revenue Estimates - Yahoo Finance
Quest Diagnostics (NYSE:DGX) Issues FY 2026 Earnings Guidance - MarketBeat
Quest Diagnostics: Fourth Quarter Earnings Overview - bitget.com
Quest Diagnostics Q4 Adjusted Earnings, Revenue Rise; 2026 Guidance Set -- Shares Up Pre-Bell - marketscreener.com
Quest Diagnostics Posts Strong 2025 Results, Boosts Shareholder Returns - TipRanks
(DGX) Quest Diagnostics Expects 2026 Revenue Range $11.7B$11.82B, vs. FactSet Est of $11.38B - marketscreener.com
(DGX) Quest Diagnostics Expects 2026 Adjusted EPS Range $10.50$10.70, vs. FactSet Est of $10.44 - marketscreener.com
Quest Diagnostics Raises Share Buyback Capacity by $1 Billion - marketscreener.com
Quest Diagnostics Raises Quarterly Dividend by 7.5% to $0.86 a Share, Payable April 20 to Shareholders of Record as of April 6 - marketscreener.com
QUEST DIAGNOSTICS ($DGX) Releases Q4 2025 Earnings - Quiver Quantitative
Quest Diagnostics Inc Stock (DGX) Financials Data
Revenue
Net Income
Cash Flow
EPS
4.06%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):